The Pharmacy Times® Pneumococcal Resource Center is a comprehensive resource for clinical news and expert insights for any infection caused by the bacteria Streptococcus pneumoniae, or pneumococcus.
March 17th 2023
Further research is needed across countries and health systems about PCV13, according to the systematic review published in Taylor & Francis Online.
Extemporaneous Compounding of Amoxicillin Suspensions During National ShortageFebruary 16th 2023
As of November 2022, amoxicillin suspension has been on a national shortage list, therefore the FDA has permitted temporary compounding of amoxicillin suspensions.
Treatment of Acute, Uncomplicated Urinary Tract Infections with Ampicillin for Vancomycin-Resistant Enterococcus SpeciesJanuary 17th 2023
The incidence of vancomycin-resistant enterococci has nearly doubled in recent years.
Expert: Long-term Care Industry Needs Help of Pharmacists to Improve Infection Prevention, ControlNovember 7th 2022
A session presenter at the ASCP 2022 Annual Meeting explained how the COVID-19 pandemic significantly magnified the importance of infection prevention and control practices in long-term care.
ASCP CEO: Pharmacy Has the Opportunity to Step Up, Fill Gaps in Care in Nursing Homes With Staffing ChallengesNovember 6th 2022
American Society of Consultant Pharmacists executive director and CEO explained how staffing struggles in long-term care facilities can be an opportunity for pharmacists to expand the ways they provide support beyond immunizations alone.
Finerenone May Protect Patients With Chronic Kidney Disease From Pneumonia-Related Severe Adverse EventsNovember 2nd 2022
The drug is a selective, nonsteroidal mineralocorticoid receptor antagonist found to also protect against COVID-19 and pneumonia-related adverse events in patients with diabetes.
FDA Approves Menveo Single-Vial Presentation for Disease Caused by Meningococcal BacteriaOctober 17th 2022
New presentation offers health care providers with a more convenient, ready-to-use immunization option for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W.
Pfizer Reports Positive Study Results for Pneumococcal Conjugate Vaccine in Infants in the EUSeptember 21st 2022
Pivotal top-line data demonstrate 20vPnC, if approved likely protects against 20 serotypes in 3-dose series and may offer the broadest serotype coverage of any PCV.
FDA Grants Breakthrough Therapy Designation to Group B Streptococcus Vaccine CandidateSeptember 12th 2022
Decision is based on interim analysis of Pfizer’s GBS6 in healthy pregnant woman aged 18 to 40 years, who were vaccinated during their second or early third trimesters.
Study: Climate Hazards Aggravate More than Half of Human Diseases Caused by PathogensAugust 25th 2022
Climatic hazards were implicated for enhancing specific aspects of pathogens, increasing capacity of pathogens to cause more severe illness, and diminishing human capacity to cope with pathogens, such as dengue, hepatitis, pneumonia, malaria, and zika.
PCV13 Vaccination May Reduce Incidence of Acute Chest Syndrome for Children with Sickle-Cell DiseaseAugust 16th 2022
A potential public health benefit of 13-valent pneumococcal conjugate vaccine is the reduction of acute chest syndrome among children with sickle-cell disease.